Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gin Hwa Biotech Inc. (7806:TWSE), powered by AI.
Gin Hwa Biotech Inc. is currently trading at $65.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Gin Hwa Biotech Inc. on Alpha Lenz.
View Gin Hwa Biotech Inc.'s valuation metrics on Alpha Lenz.
“Gin Hwa Biotech Inc.'s ROE is 12.1%. Explore profitability and growth together.”
Ask for details →Gin Hwa Biotech Inc. is a Taiwan-based company specializing in the production, sales, and contract manufacturing of health and nutritional supplements. Leveraging over 30 years of manufacturing experience, the company offers a comprehensive range of product formats—including liquid, powdered, softgel, and capsule formulations—tailored for various consumer needs. Through its original equipment manufacturer (OEM) and original design manufacturer (ODM) services, Gin Hwa Biotech collaborates with leading health product brands, providing customized formula development, new dosage form consultations, and bespoke product design. Its advanced technology portfolio features concentrated extraction, fermentation, and ultrasonic processes, all designed to ensure product effectiveness, safety, and consistency. Gin Hwa Biotech also supplies medicinal materials and food ingredients, and is active in the development of beauty and body-shaping products. Certified under ISO22000, HACCP, GMP, and FSSC 22000 standards, the company maintains strict quality controls throughout its operations. Headquartered in Kaohsiung City, Gin Hwa Biotech plays a significant role in the personal care and household health sectors, supporting both local brands and international market participants through innovation-driven contract manufacturing and ingredient solutions.
“Gin Hwa Biotech Inc.'s ROE is 12.1%. Explore profitability and growth together.”
Ask for details →Gin Hwa Biotech Inc. (ticker: 7806) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 65 with a P/E ratio of -x and P/B of -x.
ROE is 12.09% and operating margin is 17.07%. Annual revenue is $539M.